🇺🇸 FDA
Pipeline program

IMUKIN 2 X 106 UI (0,1 mg), solution injectable, SODIUM CHLORIDE

APHP220672

Phase 3 small_molecule active

Quick answer

IMUKIN 2 X 106 UI (0,1 mg), solution injectable, SODIUM CHLORIDE for Post-aggressive immunosuppression is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Post-aggressive immunosuppression
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials